Paolo De Paoli

Paolo De Paoli

Auto-generated profile, based on publicly available information

Paolo De Paoli

Scientific Directorate, Centro di Riferimento Oncologico (CRO), IRCCS, National Cancer Institute, Aviano (Pordenone) - Italy

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 1991 in Science
Verified
Journal Article
Closed access
PDF file
JBJacques Banchereau
Jacques Banchereau
PPPaolo de Paoli
Paolo de Paoli
AVAlain Vallé
Alain Vallé
EGEric Garcia
Eric Garcia
FRFrançoise Rousset
Françoise Rousset
CD40 is a 45- to 50-kilodalton transmembrane glycoprotein expressed on B lymphocytes, epithelial cells, and some carcinoma cell lines. Human resting B lymphocytes entered a state of sustained proliferation when incubated with both the mouse fibroblastic Ltk - cell line that had been transfected with the human Fc receptor (FcγRII/CDw32) and monoclonal antibodies to CD40. In combination with interleukin-4, factor-dependent long-term normal human B cell lines were generated that were consistently negative for Epstein-Barr viral infection. Thus, cross-linking of CD40 is likely to represent an important phenomenon in the clonal expansion of B cells.

1 September 1988 in Clinical Immunology and Immunopathology
Verified
Journal Article
Closed access
PPP. De Paoli
P. De Paoli
SBS. Battistin
S. Battistin
GSG.F. Santini
G.F. Santini

10 February 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GTGiuseppe Toffoli
Giuseppe Toffoli
Erika CecchinErika Cecchin
Erika Cecchin
GGGiampiero Gasparini
Giampiero Gasparini
MDMario D'Andrea
Mario D'Andrea
GAGiuseppe Azzarello
Giuseppe Azzarello
FIFederico Innocenti
Federico Innocenti
Purpose: We aimed to identify the maximum-tolerated dose (MTD) of irinotecan in patients with cancer with UGT1A1*1/*1 and *1/*28 genotypes. We hypothesize that the patients without the *28/*28 genotype tolerate higher doses of irinotecan. Patients and Methods: Patients undergoing first-line treatment for metastatic colorectal cancer (CRC) eligible for treatment with irinotecan plus infusional fluorouracil/leucovorin (FOLFIRI) were screened for the UGT1A1*28/*28 genotype and excluded from the study. Fifty-nine white patients with either the *1/*1 or the *1/*28 genotype were eligible for dose escalation of irinotecan. The starting dose of biweekly irinotecan was 215 mg/m2 for both genotype groups, whereas the dose of infusional fluorouracil was fixed. Pharmacokinetic data of irinotecan and metabolites were also obtained. Results: The dose of irinotecan was escalated to 370 mg/m2 in patients with the *1/*28 genotype and to 420 mg/m2 in those with the *1/*1 genotype. Dose-limiting toxicities (DLTs) were observed in two of four of *1/*28 patients at 370 mg/m2 and in two of three of *1/*1 patients at 420 mg/m2. No DLTs were observed in 10 *1/*28 patients at 310 mg/m2 and in 10 *1/*1 patients at 370 mg/m2; hence these dose levels were the MTD for each genotype group. The most common grade 3 to 4 toxicities were neutropenia and diarrhea. The pharmacokinetics of irinotecan and SN-38 exhibit linear kinetics. Conclusion: The recommended dose of 180 mg/m2 for irinotecan in FOLFIRI is considerably lower than the dose that can be tolerated when patients with the UGT1A1*28/*28 genotype are excluded. Prospective genotype-driven studies should test the efficacy of higher irinotecan doses in the FOLFIRI schedule.

1 February 1991 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
PPP. DE Paoli
P. DE Paoli
DGD. Gennari
D. Gennari
PMP. Martelli
P. Martelli
GBG. Basaglia
G. Basaglia
MCM. Crovatto
M. Crovatto
CSC. Santini
C. Santini
The γδ T cell receptor (TcR) lymphocytes constitute 3–10% of human peripheral blood lymphocytes. Only a very small fraction of these cells is recognized by the δTCS1 monoclonal antibody, directed against the Vγδ1 chain of the receptor. We describe the immunological, virological and clinical data of a small group of seropositive subjects having high levels of γδ TcR T cells in the peripheral blood. Our flow cytometric studies show that most of these cells belong to the δTCS1+ (Vδ1+), CD8± (dim staining) subset. Patients with high γδ TcR T cell numbers were not characterized by the presence of an acute (IgM positive) or reactivated (as defined by high IgG litres against early antigen or IgA titres against viral capsidic antigen) Epstein-Barr virus infection. Cytomegalovirus infection was excluded by serological assays, and other herpesviral infections were not found after clinical examination. HIV p24 antigenaemia was present in two out of 11 subjects. AIDS patients had very high percentages of γδ TcR T cells. Altogether these data show that the selective expansion of δTCS1+ cells in HIV1 seropositive subjects is not related to some exogenous antigen stimulation, but may be related to peculiar pathologic processes involving the immune system.

25 December 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
Massimiliano BerrettaMassimiliano Berretta
Massimiliano Berretta
CPChiara Della Pepa
Chiara Della Pepa
PTPaolo Tralongo
Paolo Tralongo
AFAlberto Fulvi
Alberto Fulvi
FMFerdinando Martellotta
Ferdinando Martellotta
GFGAETANO FACCHINI
GAETANO FACCHINI
Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey

11 March 2014 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
Antonino CarboneAntonino Carbone
Antonino Carbone
Emanuela VaccherEmanuela Vaccher
Emanuela Vaccher
Annunziata GloghiniAnnunziata Gloghini
Annunziata Gloghini
LPLiron Pantanowitz
Liron Pantanowitz
AAAkin Abayomi
Akin Abayomi
SFSilvia Franceschi
Silvia Franceschi